SF-1019
By way of an exclusive license agreement, Immunosyn Corporation has acquired from Argyll Biotechnologies, LLC the worldwide rights to market, sell and distribute SF-1019. SF-1019 is the current name of the platform technology of Argyll Biotechnologies, LLC. It was originally intended for the treatment of medical conditions related to Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Diabetic Neuropathy (DN), Diabetic Ulcers (DU), Reflex Sympathetic Dystrophy Syndrome (RSD or RSDS), also known as Complex Regional Pain Syndrome (CRPS).
SF-1019 was developed from extensive research into Biological Response Modifiers (BRMs) undertaken at: Mississippi State University; St George's, University of London (formerly St George's Hospital Medical School); Ohio University; and Methodist Hospital. The first group of BRMs was designated as Immune Cell Potentiating Factors (ICPF) and has been extensively evaluated in a number of veterinary treatments, including animal studies relating to human disease. This collaborative approach brought the thorough and unbiased scrutiny of the scientific and medical community upon the related research and particularly SF-1019. It is the opinion of Argyll Biotechnologies, LLC, that these data collectively support the conclusion that SF-1019, as a BRM, may point the way for the future development and refinement of many promising innovative and cutting-edge therapeutics, which are also included in our exclusive license agreement.
SF-1019 is believed to be one of a new class of therapeutics made from mammalian cells. As an isolated compound, SF-1019 is comprised of low molecular weight lipo-peptides. Pre-clinical human studies and clinical trials in animals have shown SF-1019 to provide therapeutic benefits without toxic or pyrogenic (fever-causing) effects at therapeutically effective dosages. In animal studies, once injected subcutaneously, SF-1019 produces an immunomodulatory cascade, which generates a prophylactic and/or therapeutic benefit. In pre-clinical human studies, it appears to create a therapeutic affective response over a range of demyelinating conditions of the peripheral nervous system (PNS) resulting in rapid reduction of symptoms. A major benefit of SF-1019 is its perceived ability to simultaneously target, activate and support the modulation of both the innate and adaptive immune systems, having a dramatic effect on many neurological and demyelinating conditions. Research suggests the current product has additional developmental potential as it also possesses analgesic properties with an ability to substantially reduce the inflammation attending a number of clinical conditions including Multiple Sclerosis (MS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Reflex Sympathetic Dystrophy Syndrome, (RSD or RSDS) and other auto-immune and neurological disorders.
Argyll Biotechnologies, LLC has initiated the approval process in several countries and preparations for clinical trials in humans are underway in both the US and Europe with plans to develop a series of new products from Argyll Biotechnologies, LLC’s proprietary platform technology and other licensed techniques. These trials are the first of a planned new SF-1019 based product series designed to treat or improve the quality of life and the clinical management of a number of auto-immune and neurological disorders and other human diseases. The current iteration of SF-1019 and any future variants developed in this series of new products that may be developed by Argyll Biotechnologies, LLC are covered in the exclusive, worldwide license agreement which has been granted to Immunosyn. Argyll Biotechnologies, LLC will continue to pursue regulatory approval for SF-1019 with the compassionate goal of SF-1019 potentially becoming a first line defense for mainstream medical practitioners.
